AVITA Medical/$RCEL
1D1W1MYTD1Y5YMAX
Capital at risk
About AVITA Medical
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
- Ticker
- $RCEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Valencia, United States
- Website
- avitamedical.com
AVITA Medical Metrics
BasicAdvanced
$341M
-
-$1.44
2.02
-
Price and volume
Market cap
$341M
Beta
2.02
52-week high
$11.39
52-week low
$3.22
Average daily volume
626K
Financial strength
Current ratio
0.413
Quick ratio
0.306
Long term debt to equity
-0.065
Total debt to equity
-1.742
Interest coverage (TTM)
-4.45%
Profitability
EBITDA (TTM)
-32.764
Gross margin (TTM)
81.56%
Net profit margin (TTM)
-56.96%
Operating margin (TTM)
-46.56%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-41.56%
Return on equity (TTM)
211.55%
Valuation
Price to revenue (TTM)
4.369
Price to book
-12.24
Price to tangible book (TTM)
-10.3
Price to free cash flow (TTM)
-13.04
Free cash flow yield (TTM)
-7.67%
Free cash flow per share (TTM)
-0.845
Growth
Revenue change (TTM)
1.00%
Earnings per share change (TTM)
-26.91%
3-year revenue growth (CAGR)
22.79%
3-year earnings per share growth (CAGR)
5.74%
What the Analysts think about AVITA Medical
Analyst ratings (Buy, Hold, Sell) for AVITA Medical stock.
Analyst projections of the future price of AVITA Medical stock.
Bulls say / Bears say
Q2 revenue reached a record $21.7 million, up 18% year on year and 13% sequentially. AVITA raised 2026 revenue guidance to $86–89 million, implying 20–24% growth over 2025. (GlobeNewswire)
RECELL utilisation is improving as reimbursement becomes more predictable, while RECELL GO mini is expanding treatment into smaller wounds. Proposed 2027 CMS rules could replace regional pricing with nationally published physician payments and higher facility rates, reducing a major adoption barrier if finalised. (GlobeNewswire, Exa)
AVITA is building a broader wound-care offering around RECELL, with Cohealyx and PermeaDerm gaining traction. Interim Cohealyx data showed patients reached skin-grafting readiness about 20 days sooner than with leading competing products, which could support adoption and cross-selling into existing hospital accounts. (GlobeNewswire, InvestingNews)
The balance sheet remains fragile: the June quarter ended with only about $11.1 million of cash and marketable securities against a large debt obligation. Management disclosed substantial doubt about the company’s ability to continue as a going concern, creating refinancing and dilution risk if the turnaround slips. (StockTitan, Last10K)
RECELL still accounts for most of quarterly revenue: $18.5 million of the $21.7 million total in Q2. The newer products are growing but remain too small to offset the risk of a setback in the company’s core product. (GlobeNewswire, EveryTicker)
The reimbursement improvement is not fully locked in: the national 2027 CMS framework is still only proposed and its final payment levels could differ. AVITA also remains loss-making, so it must deliver the forecast revenue growth and Q4 cash-flow break-even while converting relatively limited multi-product hospital adoption into repeat demand. (Last10K, Transcript Daily)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
AVITA Medical Financial Performance
Revenues and expenses
AVITA Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
AVITA Medical News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.